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Abstract
Background. Substantial clinical heterogeneity of major depressive disorder (MDD) suggests
it may group together individuals with diverse aetiologies. Identifying distinct subtypes should
lead to more effective diagnosis and treatment, while providing more useful targets for further
research. Genetic and clinical overlap between MDD and schizophrenia (SCZ) suggests an
MDD subtype may share underlying mechanisms with SCZ.
Methods. The present study investigated whether a neurobiologically distinct subtype of
MDD could be identified by SCZ polygenic risk score (PRS). We explored interactive effects
between SCZ PRS and MDD case/control status on a range of cortical, subcortical and white
matter metrics among 2370 male and 2574 female UK Biobank participants.
Results. There was a significant SCZ PRS by MDD interaction for rostral anterior cingulate
cortex (RACC) thickness (β = 0.191, q = 0.043). This was driven by a positive association
between SCZ PRS and RACC thickness among MDD cases (β = 0.098, p = 0.026), compared
to a negative association among controls (β =−0.087, p = 0.002). MDD cases with low SCZ
PRS showed thinner RACC, although the opposite difference for high-SCZ-PRS cases was
not significant. There were nominal interactions for other brain metrics, but none remained
significant after correcting for multiple comparisons.
Conclusions. Our significant results indicate that MDD case-control differences in RACC
thickness vary as a function of SCZ PRS. Although this was not the case for most other
brain measures assessed, our specific findings still provide some further evidence that
MDD in the presence of high genetic risk for SCZ is subtly neurobiologically distinct from
MDD in general.
Major depressive disorder (MDD) is a prevalent and frequently disabling psychiatric disorder,
associated with prolonged low mood, although many unique symptom combinations may lead
to the same diagnosis (Gallo and Rabins, 1999; Kennedy, 2008). The high clinical heterogen-
eity suggests that MDD may group together a number of disease subtypes (Fava et al., 1997;
Baumeister and Parker, 2012; van Loo et al., 2014). Differences in clinical presentation may
reflect differences in aetiology and underlying neurobiological mechanisms. Identifying
subtypes of MDD is therefore likely to be a crucial step toward more effective diagnosis and
treatment of affected individuals, as well as providing better targets for genomic and neurobio-
logical studies.
The heritability of MDD is estimated to be about 37% (Sullivan et al., 2000), determined by
a large number of alleles each of small effect (Ripke et al., 2013). MDD subtypes may differ in
terms of which alleles (Flint and Kendler, 2014) and which biological mechanisms (Hasler
et al., 2004) are involved. For example, Milaneschi et al. (2017) demonstrated only a very
small genetic overlap between typical MDD (associated with decreased appetite and weight)
and an atypical subtype (associated with increased appetite and weight). Focusing more spe-
cifically on stratifying MDD by genetic factors, Howard et al. (2017) recently identified 10 vari-
ables related to genetic subgroups that might partly account for the heterogeneity of MDD.
Further investigation of specific genetic subgroups may help to identify more clinically and
empirically useful MDD subtypes.
Some genes that contribute to MDD overlap with those underlying schizophrenia (SCZ;
Schulze et al., 2014) and the two disorders have a genetic correlation of rg = 0.43
(Cross-Disorder Group of the Psychiatric Genetics Consortium et al., 2013). Individuals
with MDD also at high polygenic risk of SCZ have been previously shown to differ in
terms of clinical and behavioural phenotypes. Whalley et al. (2016) observed higher
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neuroticism and psychological distress among controls with a
higher SCZ polygenic risk score (PRS), but not among
high-SCZ-PRS MDD cases. Additionally, Power et al. (2017)
found that MDD subtypes based on age of onset differed in
terms of SCZ PRS, and early-onset cases have been found to
show greater deficits in frontal (Jaworska et al., 2014) and limbic
(MacMaster et al., 2008; Clark et al., 2018) regions. This may sug-
gest a different aetiology and perhaps different neurobiological
profile of MDD in the presence of high genetic risk for SCZ,
i.e. an SCZ-risk-related MDD subtype. It seems that some of
the genes that may contribute to both SCZ and MDD are involved
in regulating synaptic function and the excitability of prefrontal
neurons (Howard et al., 2019). However, whether subtypes of
MDD based on genetic loading for SCZ are distinct in terms of
brain structure has yet to be determined.
MDD is typically associated with fronto-limbic deficits, includ-
ing reduced cortical volume/thickness in prefrontal regions
(Salvadore et al., 2011; Rodriguez-Cano et al., 2014; Schmaal
et al., 2017), and smaller subcortical limbic structures (Kim
et al., 2008; Lu et al., 2016; Schmaal et al., 2016). Reductions in
integrity of connecting white matter tracts have also been
observed (Cole et al., 2012; Bessette et al., 2014; Shen et al.,
2017). Fronto-limbic impairments are also apparent in SCZ
(Ross et al., 2006; Keshavan et al., 2008; Yao et al., 2013), along
with more widespread white matter deficits (Ellison-Wright and
Bullmore, 2009) and greater cortical reductions in temporal
regions (Wong and van Tol, 2003). Furthermore, some SCZ-like
neuroimaging markers, such as reduced hippocampal, thalamic
and prefrontal volumes, appear in individuals who are genetically
predisposed to SCZ but remain healthy (Lawrie et al., 2001; Boos
et al., 2007). As of yet, the influences of SCZ risk on such neuro-
biological measures in the presence of MDD are unclear.
Following on from previous work stratifying MDD traits by
PRS for SCZ (Whalley et al., 2016), we aimed to measure the neu-
roimaging associations of MDD as a function of SCZ PRS, testing
for further evidence of MDD subtype heterogeneity related to
SCZ risk. We assessed interactive effects between SCZ PRS and
MDD case/control status on measures of cortical, subcortical
and white matter structure. Based on previous evidence of neuroi-
maging abnormalities in healthy subjects at high genetic risk for
SCZ (Lawrie et al., 2001; Boos et al., 2007), we expected negative
correlations between SCZ PRS and brain measures among both
cases and controls, with significant interactions between MDD
and SCZ PRS indicating a specific subtype. Without any specific
hypotheses regarding the neurobiological bases of differences in
neuroticism and distress among high-SCZ-risk MDD cases, we
took an exploratory approach, testing SCZ PRS by MDD interac-
tions for structural measures covering the entire brain. We did,
however, anticipate interactions in areas that normally show def-
icits in MDD, such as frontal cortical regions, limbic structures
and connecting white matter tracts. Any significant interactions,
indicating that MDD’s associations with neuroimaging measures
differed as a function of SCZ PRS, would provide evidence of
an SCZ-risk-related MDD subtype.
Methods
Participants
Data were derived from 4944 participants in the large-scale
prospective epidemiological study, UK Biobank (http://www/
ukbiobank.ac.uk). UK Biobank includes data on 503 325 members
of the general UK population, recruited between 2006 and 2010
(Allen et al., 2012). Participants originally provided information
on a wide range of health, lifestyle, environment and other vari-
ables, and the majority have also provided genetic data. The pro-
ject aims to submit approximately 100 000 of the participants to a
full-body imaging protocol, which includes the acquisition of neu-
roimaging data in several modalities (Miller et al., 2016). The pre-
sent study focused on 4944 UK Biobank participants for whom
both genetic and brain imaging data have already been acquired,
who also had data on MDD and relevant covariates, described
below. Participants who reported a diagnosis of schizophrenia
were excluded from all analyses. Descriptive statistics for included
participants are reported in Table 1.
Polygenic risk for schizophrenia
UK Biobank blood samples were genotyped using either the UK
BiLEVE array or UK Biobank Axiom array, and quality controlled
at the Wellcome Trust Centre for Human Genetics (Wain et al.,
2015; Hagenaars et al., 2016). Further quality control measures
included removal of participants based on missingness, related-
ness, non-British ancestry and gender mismatch. Subsequent pro-
cessing involved removal of SNPs with minor allele frequency
<1%, and clump-based linkage disequilibrium pruning (r2 < 0.25
within a 200 bp window). PRSs for SCZ were calculated for
each participant using PRSice (Euesden et al., 2015) and genome-
wide association study summary data (Schizophrenia Working
Group of the Psychiatric Genetics Consortium, 2014), including
SNPs selected according to the significance of their associations
with the phenotype at thresholds of p < 0.01, p < 0.05, p < 0.10,
p < 0.50 and all SNPs.
Major depressive disorder
As part of a web-based mental health questionnaire, UK Biobank
participants completed the short form of the Composite
International Diagnostic Interview (CIDI-SF; Kessler et al.,
1998). Section A of the CIDI-SF focuses on MDD symptomatol-
ogy, providing a score of between zero and eight. Participants with
a score of five or more were classified as lifelong MDD cases;
those with a score of four or less as controls. Participants who
scored highly but did not report having experienced core symp-
toms of either low mood or anhedonia were excluded. CIDI-SF
controls who had previously reported a past diagnosis of depres-
sion or showed signs of MDD on the 9-item Patient Health
Questionnaire (PHQ-9; Kroenke et al., 2001) were also excluded
(N = 286). The resulting CIDI-assessed measure of MDD there-
fore included 1674 cases and 3270 controls (Table 1). Some of
the earlier scanned subjects completed the web-based question-
naire up to 2.7 years later, but most completed it within a year
of imaging data acquisition.
Brain imaging data
Full information on imaging data acquisition and processing are
provided in supplementary materials and previous publications
(Miller et al., 2016; Alfaro-Almagro et al., 2018). To summarise,
all structural and diffusion data were acquired on the same 3T
scanner using the same protocol. Cortical metrics for 27 regions
(N = 1877) were derived locally using FreeSurfer version 5.3
(Dale et al., 1999; Fischl et al., 1999, 2004; Desikan et al.,
2006). Volumes of seven subcortical structures (N = 4944) were
2 Mathew A. Harris et al.
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derived by the UK Biobank imaging team using FIRST
(Patenaude et al., 2011). Fractional anisotropy (FA) and mean dif-
fusivity (MD) of 15 white matter tracts (N = 4420) were also
derived by the UK Biobank imaging team using bedpostx and
probtrackx (Behrens et al., 2007), and then AutoPtx (de Groot
et al., 2013).
At the time of beginning this study, subcortical volumes and
white matter metrics were available for the first two releases of
UK Biobank imaging data, while cortical metrics were available
for only the first release. Following initial submission of our
results for publication, cortical metrics became available for the
second release as well, including for 794 MDD cases and 1604
controls who met the criteria for inclusion in this study. We
have therefore used these additional data to replicate any signifi-
cant findings discovered in the first release.
Additional covariates
In relation to SCZ PRS, genotyping array and the first 15 ancestry
principal components (controlling for population stratification
within the sample) were included as covariates in all analyses.
We used as many as 15 principal components to control for the
substantial genetic clustering recently found in UK Biobank
(Abdellaoui et al., 2018). Including more than 15 made negligible
difference to our results. In relation to neuroimaging data, x, y and
z coordinates of head position within the MRI scanner were
included as covariates, along with a measure of whole-brain vol-
ume (including grey matter, white matter and ventricles), derived
from the UK Biobank image processing pipeline (Alfaro-Almagro
et al., 2018). Additionally, age in years at time of scanning, age2
and sex were included in all analyses.
Statistical analysis
Data were analysed in R version 3.2.3 (R Core Team, 2013). As
additional quality control, outliers, defined as further than three
standard deviations from the mean, were removed from all neu-
roimaging measures. Left and right measures were then combined
bilaterally, as above; a general lack of hemispheric effects in the
same UK Biobank subcortical and white matter phenotypes has
been reported previously (Shen et al., 2017). We performed ana-
lyses of case-control differences in group size, sex and SCZ PRS,
reported in Table 1. For each regional brain measure and each
PRS threshold, we then ran linear regression models to estimate
the strength of the interactive effect between SCZ PRS and
MDD in all participants, controlling for the main effects of
each, as well as effects of age, age2, genotyping array, the first
15 principal components of genetic ancestry, whole-brain volume
and scanner head position coordinates. FDR correction was
applied to p values across all interaction effects together.
As main effects of SCZ PRS among MDD cases would not
demonstrate whether the effects were specific to cases, only inter-
actions between MDD and SCZ PRS could provide indications of
aetiological differences between MDD cases at high and low SCZ
risk. However, where interactions were significant, we assessed
main effects of SCZ PRS among MDD cases and controls separ-
ately, and tested case-control differences among those above and
below mean SCZ PRS. Together, these analyses provided further
information on how MDD and SCZ risk interact. We additionally
tested whether significant interactions were influenced by a sub-
group of MDD cases with both repeated k-mean and hierarchical
cluster analyses, using package ‘fpc’ (Henning, 2015) in addition
to base packages. Further packages ‘ggplot2’ (Wickham and
Chang, 2016) and ‘ellipse’ (Murdoch and Chow, 2013) were
Table 1. Descriptive statistics for MDD cases and controls, and group differences
Cases Controls Difference
Subjects (N, %) 1674 (33.86) 3270 (66.14) χ21 = 1029.10, p < 0.001 ***
Age (years; M, S.D.) 61.23 (7.20) 63.69 (7.21) t3249 =−11.15, p < 0.001 ***
Sex (N, %)
Males 625 (37.34) 1745 (53.36) χ21 = 113.33, p < 0.001 ***
Females 1049 (62.66) 1525 (46.64)
WBV (cm3; M, S.D.) 1194.91 (111.77) 1212.24 (114.99) t3458 =−5.11, p < 0.001 ***
SCZ PRS (z-score; M, S.D.)
Threshold 0.01 0.03 (0.98) −0.03 (1.01) t3457 = 1.87, p = 0.06
Threshold 0.05 0.02 (0.98) −0.03 (1.01) t3476 = 1.91, p = 0.06
Threshold 0.10 0.03 (0.98) −0.04 (1.02) t3482 = 2.28, p = 0.02 *
Threshold 0.50 0.03 (0.99) −0.05 (1.01) t3430 = 2.91, p < 0.01 **
All SNPs 0.04 (0.99) −0.05 (1.01) t3428 = 3.01, p < 0.01 **
Imaging data (N, %)
Cortical metrics 640 (38.23) 1237 (37.83) χ21 = 0.09, p = 0.77
(replication sample) 794 (49.50) 1604 (51.19) χ21 = 1.16, p = 0.28
Subcortical volumes 1674 (100.00) 3270 (100.00) χ21 = 0.00, p > 0.99
DTI measures 1474 (88.05) 2946 (90.09) χ21 = 0.55, p = 0.79
MDD, major depressive disorder; WBV, whole brain volume; SCZ, schizophrenia; PRS, polygenic risk score; DTI, diffusion tensor imaging.
Group differences were assessed using χ2 tests and two-sample t tests.
*, ** and *** represent significant results at p < 0.05, p < 0.01 and p < 0.001, respectively
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also used to create figures. Results are reported in terms of stan-
dardised β coefficients, and p values and q values (FDR-corrected
p values) <0.05 are considered significant.
Results
Descriptive statistics are reported for MDD cases and controls in
Table 1. MDD cases were younger than controls (t3252 =−11.15,
p < 0.001), a higher proportion of cases were female (χ21 = 113.33,
p < 0.001), and WBV was lower among cases (t3460 = 5.11, p <
0.001). These variables were controlled in all subsequent analyses.
Mean PRS was slightly higher among cases at thresholds 0.10
(t3484 = 2.28, p = 0.02), 0.50 (t3430 = 2.91, p < 0.01) and all SNPs
(t3427 = 3.01, p < 0.01). All SCZ PRS by MDD interactions tested
for both MDD measures are summarised in Fig. 1; within each
measure, fronto-limbic areas are presented first.
Cortical regions
Analyses of cortical metrics focused on a subset of 1877 subjects
for whom these data were available. We first assessed interactive
effects between SCZ PRS and MDD on regional mean cortical
thickness. There were significant interactive effects across multiple
PRS thresholds of at least β = 0.132 ( p = 0.009) in rostral ACC,
β = 0.101 ( p = 0.042) in superior temporal gyrus and β = 0.120
( p = 0.037) in entorhinal cortex (Table 2). The interaction in
rostral ACC was significant across all thresholds and the two
strongest of these effects remained significant after FDR correc-
tion: for PRS threshold 0.50 (β = 0.191, q = 0.043) and for all
SNPs (β = 0.191, q = 0.043). These interactions were driven by sig-
nificant negative effects of β =−0.094 ( p = 0.001) and β =−0.090
( p = 0.002) among controls, but positive effects of β = 0.103 ( p =
0.017) and β = 0.109 ( p = 0.013) among cases. These results mean
that greater SCZ PRS was associated with thinner rostral ACC in
controls, but not in MDD cases (Fig. 2). Paired t tests confirmed
that the case-control difference was significant at PRS thresholds
0.05 (t111 = 2.590, p = 0.011) and 0.50 (t111 = 2.289, p = 0.024)
among those of below-average SCZ PRS, but not at any threshold
for those of above-average SCZ PRS.
Given the specific effect of SCZ PRS on rostral ACC mean
thickness among MDD cases, we tested whether it was influenced
by a subgroup of participants. Repeated k-means clustering of
SCZ PRS and rostral ACC thickness data using the function
‘pamk’ identified three as the optimum (according to average sil-
houette width; also verified using hierarchical clustering) for each
of the three thresholds showing significant interactions. However,
as shown in online Supplementary Fig. S1, for each threshold,
none of the three clusters clearly represented a high-SCZ-risk sub-
group, and none was significantly distinct from the other two,
with low Dunn indices (DIs) of 0.009.
Asmore cortical data became available later, wewere able to retest
the interaction between SCZ PRS and MDD on rostral ACC thick-
ness in a replication sample. The interaction was weaker but signifi-
cant for SCZ PRS thresholds 0.05 (β = 0.095, p = 0.024) and 0.10
(β = 0.083, p = 0.047). As shown in online Supplementary Fig. S2,
the interaction was attenuated mainly by the controls of the
replication sample, among whom the negative association between
SCZ PRS and rostral ACC thickness was much closer to zero than
in the discovery sample (β =−0.013, p = 0.595; β =−0.009, p =
0.724). The association amongMDD cases of the replication sample
was still positive, but alsoweaker than in thediscovery sample andno
longer significant (β = 0.065, p = 0.074; β = 0.057, p = 0.116).
For cortical surface area, there were significant interactions
across multiple PRS thresholds of β =−0.091 ( p = 0.014) to
β = −0.105 ( p = 0.005) in inferior frontal gyrus (IFG), again due
to a stronger negative effect of SCZ PRS among MDD cases
than controls, but these results failed to survive FDR correction.
Full results are reported in online Supplementary Table S1.
For cortical volume, there were significant interactions across
multiple PRS thresholds of β = −0.088 ( p = 0.020) and β = −0.090
( p = 0.017) for IFG, β = 0.091 ( p = 0.029) and β = 0.094
( p = 0.026) for rostral ACC; and β = 0.098 ( p = 0.035) to
β = 0.110 ( p = 0.017) for caudal ACC.However, following FDRcor-
rection, none of these interactive effects on regional cortical
volumes remained significant (online Supplementary Table S2).
Subcortical structures
We next tested interactive effects on subcortical volumes, which
were available for all 4944 subjects. Across all subcortical volumes
and PRS thresholds, there was only one significant SCZ PRS by
MDD interaction: a weak positive interactive effect of β = 0.047
( p = 0.016) on thalamic volume at PRS threshold 0.01 (online
Supplementary Table S3). This was driven by weak and non-
significant but opposite associations between SCZ PRS and thal-
amic volume in MDD cases (β = 0.030) and controls (β =−0.022),
but the interaction did not remain significant after FDR correction.
White matter tracts
Finally, we explored interactions in white matter tracts for the
4420 subjects with DTI data. There were no significant interactive
Fig. 1. Significance of SCZ PRS by MDD interactions on all cortical, subcortical and
white matter metrics. SCZ, schizophrenia; PRS, polygenic risk score; MDD, major
depressive disorder; CT, cortical thickness; CSA, cortical surface area; CV, cortical vol-
ume; SCV, subcortical volume; FA, fractional anisotropy; MD, mean diffusivity. Results
for fronto-limbic brain regions are presented first in red/darker grey, followed by all
other brain regions in blue/lighter grey. Points above the lower dashed line represent
results that were significant before correcting for multiple comparisons ( p < 0.05).
Points representing significant results after FDR correction (q < 0.05) are circled.
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Table 2. Interactive effects between SCZ PRS and MDD status on mean cortical thickness by region
PRS threshold 0.01 PRS threshold 0.05 PRS threshold 0.10 PRS threshold 0.50 PRS all SNPs
β S.E. p β S.E. p β S.E. p β S.E. p β S.E. p
Dorsolateral PFC 0.052 0.046 0.263 0.027 0.046 0.563 0.054 0.047 0.251 0.063 0.046 0.173 0.061 0.046 0.190
Caudal MFG 0.043 0.046 0.347 0.018 0.046 0.703 0.041 0.047 0.386 0.036 0.046 0.433 0.030 0.046 0.518
IFG 0.039 0.047 0.408 0.012 0.047 0.798 0.046 0.047 0.335 0.017 0.047 0.710 0.018 0.047 0.694
Lateral OFC 0.032 0.049 0.519 0.023 0.050 0.646 0.030 0.050 0.553 0.010 0.050 0.848 0.011 0.050 0.830
Medial OFC 0.093 0.051 0.070 0.047 0.052 0.363 0.045 0.052 0.387 0.073 0.052 0.159 0.070 0.052 0.176
Frontal pole 0.091 0.049 0.066 0.006 0.050 0.902 0.035 0.050 0.486 0.055 0.049 0.262 0.053 0.050 0.289
Rostral ACC 0.132 0.050 0.009** 0.154 0.050 0.002** 0.179 0.051 <0.001*** 0.191 0.050 <0.001*** 0.191 0.050 <0.001***
Caudal ACC 0.050 0.048 0.293 0.038 0.048 0.434 0.028 0.049 0.570 0.023 0.048 0.630 0.012 0.048 0.805
Posterior cingulate −0.032 0.048 0.501 −0.042 0.048 0.389 −0.019 0.049 0.700 −0.017 0.048 0.718 −0.015 0.048 0.756
Isthmus cingulate −0.040 0.048 0.408 −0.070 0.048 0.147 −0.040 0.049 0.413 −0.050 0.048 0.294 −0.038 0.048 0.424
Precentral 0.056 0.047 0.238 0.034 0.048 0.474 0.057 0.048 0.235 0.042 0.047 0.377 0.047 0.047 0.327
Postcentral 0.094 0.048 0.051 0.070 0.048 0.148 0.091 0.049 0.065 0.090 0.048 0.060 0.100 0.048 0.038*
Paracentral 0.087 0.048 0.072 0.054 0.049 0.265 0.069 0.049 0.158 0.055 0.048 0.253 0.056 0.049 0.249
Precuneus 0.022 0.046 0.639 0.008 0.046 0.870 0.013 0.047 0.774 0.011 0.046 0.812 0.009 0.046 0.852
Superior parietal 0.038 0.047 0.424 0.033 0.047 0.487 0.039 0.048 0.413 0.028 0.047 0.550 0.030 0.047 0.533
Inferior parietal 0.039 0.045 0.385 0.028 0.045 0.533 0.060 0.045 0.187 0.043 0.045 0.341 0.041 0.045 0.362
Supramarginal 0.074 0.046 0.110 0.040 0.047 0.395 0.083 0.047 0.078 0.088 0.046 0.058 0.091 0.046 0.050
Insula 0.004 0.051 0.937 −0.016 0.051 0.753 0.019 0.052 0.711 −0.021 0.051 0.685 −0.017 0.051 0.737
STG 0.101 0.050 0.042* 0.108 0.050 0.032* 0.107 0.051 0.035* 0.085 0.050 0.090 0.087 0.050 0.085
MTG 0.043 0.049 0.371 0.081 0.049 0.100 0.091 0.050 0.066 0.075 0.049 0.125 0.078 0.049 0.111
ITG 0.007 0.053 0.896 0.009 0.053 0.869 0.033 0.054 0.541 0.007 0.053 0.899 0.000 0.053 >0.999
Fusiform −0.020 0.054 0.706 −0.030 0.054 0.575 −0.009 0.055 0.874 −0.027 0.055 0.628 −0.025 0.055 0.645
Entorhinal 0.070 0.057 0.218 0.096 0.058 0.097 0.125 0.058 0.032* 0.120 0.057 0.037* 0.120 0.057 0.037*
Parahippocampal −0.083 0.051 0.105 −0.048 0.052 0.354 −0.009 0.052 0.864 0.013 0.052 0.794 0.014 0.052 0.785
Temporal pole −0.005 0.050 0.922 0.056 0.050 0.268 0.076 0.051 0.135 0.081 0.050 0.106 0.075 0.050 0.133
Lateral occipital −0.004 0.046 0.925 −0.006 0.047 0.895 0.012 0.047 0.802 −0.008 0.047 0.861 −0.009 0.047 0.850
Medial occipital −0.027 0.048 0.577 −0.048 0.049 0.327 −0.028 0.049 0.573 −0.023 0.048 0.634 −0.020 0.049 0.673
SCZ, schizophrenia; PRS, polygenic risk score; MDD, major depressive disorder; PFC, prefrontal cortex; MFG, middle frontal gyrus; IFG, inferior frontal gyrus; OFC, orbitofrontal cortex; ACC, anterior cingulate cortex; STG, superior temporal gyrus;
MTG, middle temporal gyrus; ITG, inferior temporal gyrus.
Reported results are for interactive effects between SCZ PRS and MDD status on regional mean cortical thickness, controlling covariates.
*,** and *** represent significant results at p < 0.05, p < 0.01 and p < 0.001, respectively, before correcting for multiple comparisons. Significant results after FDR correction are highlighted in bold.
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effects between SCZ PRS and MDD on the FA of any of the
white matter tracts at any of the PRS thresholds (online
Supplementary Table S4). For MD, there was a significant
interactive effect of β = 0.057 ( p = 0.045) at threshold 0.50 and
β = 0.061 ( p = 0.033) with all SNPs in the uncinate fasciculus
(online Supplementary Table S5). Uncinate MD also showed
weak and non-significant opposite effects of SCZ PRS in
MDD cases (β = 0.037; β = 0.035) and controls (β =−0.024;
β =−0.030). No results survived correction formultiple comparisons.
Discussion
Following on from findings that MDD differs behaviourally as a
function of genetic risk for SCZ, we tested interactions between
SCZ PRS and MDD status on a range of brain structure measures
in a large sample of UK Biobank participants. Interactions were
not significant for most brain measures, but results for rostral
ACC mean thickness at two PRS thresholds remained significant
after correction for multiple comparisons. In rostral ACC, greater
SCZ PRS showed a weak association with thinner cortex among
controls, but a weak association with thicker cortex among
MDD cases. However, MDD cases and controls only completely
diverged toward the lower end of the range in SCZ PRS, where
cases still showed thinner rostral ACC. We were able to replicate
this interaction in a second subsample, although the effect was
attenuated. This significant result seems to indicate localised
reserve or protection against the negative neurostructural effects
of SCZ-associated genes among individuals with MDD, but alter-
native explanations are discussed below.
We focused on interactions between SCZ PRS and MDD, but
also tested main effects of SCZ PRS within MDD case and control
groups for significant interactions. For controls, results suggested
that a higher SCZ PRS was associated with reductions in rostral
ACC thickness, as expected. These results are consistent with
the reductions in prefrontal volumes seen in SCZ (Ross et al.,
2006; Keshavan et al., 2008), and therefore with previous evidence
of schizophrenia-like neuromorphology among high-risk but
healthy controls (Lawrie et al., 2001; Boos et al., 2007). Further,
case-control t tests clearly showed deficits in rostral ACC thick-
ness among MDD cases with a low SCZ PRS, compared to
low-SCZ-risk controls. This is also expected and consistent with
previous evidence of reduced cingulate grey matter (Salvadore
et al., 2011; Rodriguez-Cano et al., 2014; Schmaal et al., 2017)
in MDD. However, others have observed increased thickness of
rostral ACC in MDD (Ancelin et al., 2019) and of other cortical
regions in SCZ (Dukart et al., 2017), which does correspond to
our findings among individuals at higher genetic risk of SCZ.
Increased rostral ACC thickness among individuals with both
MDD and a high genetic predisposition to SCZ may initially seem
counterintuitive, suggesting that two putative neuropathologies
instead confer benefits when combined. However, while positive
associations between SCZ PRS and brain measures among indivi-
duals with MDD also stand in contrast with most previous find-
ings (as above), some previous findings are comparable. For
example, Papmeyer et al. (2015) reported thickening of inferior
frontal and precentral cortices among individuals with both
MDD and familial risk of bipolar disorder. One possible explan-
ation is that the subset of MDD cases with a higher SCZ PRS in
this study included individuals who had not developed SCZ des-
pite a high level of genetic predisposition. These individuals may
have had a neurobiological advantage over others at high genetic
risk who did develop SCZ, who were not included in the study.
Resistance to aberrant neurodevelopmental influences could
explain both why high-SCZ-risk MDD cases did not develop
SCZ and why they were more comparable to controls than to
low-SCZ-risk cases. Or, simply, the greater rostral ACC thickness
observed among high-SCZ-risk MDD cases may have protected
against more severe psychopathology. However, as only a small
Fig. 2. Mean thickness by SCZ PRS and MDD group for the two significant SCZ PRS by MDD interactions in rostral anterior cingulate cortex. SCZ, schizophrenia; PRS,
polygenic risk score; MDD, major depressive disorder; RACC, rostral anterior cingulate cortex. Lines represent least-squares regression lines (red/darker grey = MDD
cases; blue/lighter grey = controls); shaded areas represent 95% confidence intervals. Plots illustrate the two significant interactions between SCZ PRS at threshold
0.5 (left) or including all SNPs (right), and MDD status on RACC mean thickness.
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proportion of individuals develop SCZ – even among those with a
higher PRS – their exclusion is unlikely to have had such an
impact on our results.
Alternatively, it may be that the increase in rostral ACC thickness
that we observed does not actually represent a benefit. Increased
thickness and functional connectivity of rostral ACC have been
associated with insomnia (Winkelman et al., 2013) and delusions
in SCZ (Schott et al., 2015), respectively. Such symptoms may relate
to a deficit in, for example, normal axonal pruning, as this could
lead to increased cortical thickness. Some theories of SCZ associate
the disorder with altered pruning throughout development
(Feinberg, 1982; Keshavan et al., 1994; Glausier and Lewis, 2013),
although they typically attribute it to excessive pruning, rather
than decreased pruning. However, disruption of normal neurodeve-
lopmental mechanisms could lead to excessive pruning in some
areas but decreased pruning in others. While this could in turn
lead to greater cortical thickness, these increases might be associated
with aberrant hyperactivity or reduced efficiency, contributing to
psychiatric symptoms. Further results do suggest SCZ-related
increases in thickness and volume of specific brain regions, such
as superior parietal cortex and the amygdala (Spoletini et al.,
2011; van Haren et al., 2011), supporting this account. Increases
in ACC thickness have also been observed with ageing in some stud-
ies (Salat et al., 2004; Abe et al., 2008). Whether our results relate to
a benefit or impairment specifically among high-SCZ-risk MDD
cases, they provide some evidence of an SCZ-risk-related MDD
subtype distinct in terms of prefrontal morphology.
Considering that MDD cases and controls only completely
diverged at the lower end of the SCZ PRS scale, it may be that
case-control differences in rostral ACC thickness were not
reversed at the higher end of the range in SCZ PRS, but merely
attenuated. In this case, the results relate more directly to
Whalley et al.’s (2016) findings of attenuated case-control differ-
ences in neuroticism and psychological distress at higher SCZ
PRS. This rekindles the idea that both sets of findings represent
a protective effect of genetic risk for SCZ among MDD cases,
and although it remains unclear why SCZ risk might be protect-
ive, the correspondence between clinical and neuroimaging find-
ings strengthens evidence for a possible SCZ-risk-related MDD
subtype. Although our cluster analyses were not able to distin-
guish this subtype, it warrants further investigation.
For most other structural brain metrics assessed, however, we
found no significant influence of SCZ PRS on MDD case-control
differences. This may have been due to limitations of the study.
We used data from UK Biobank, which recruited large numbers
of participants from the general population, but our sample
(and particularly the smaller subset with data on cortical metrics)
may not have been large enough to detect subtle genetic effects.
The generalizability of results from UK Biobank is also still poten-
tially limited by selection bias (Allen et al., 2012), as the sample is
healthier overall than the general population (Fry et al., 2017).
This is a common limitation to most observational studies but,
as Fry et al. argue, results are likely to be both robust and widely
generalizable. However, a limitation of recruiting from the general
population is that SCZ PRS may not have been particularly high
for any of our subjects. We still found significant heterogeneity in
MDD related to SCZ PRS despite this, which perhaps lends fur-
ther weight to the conclusion drawn from our significant results
for rostral ACC thickness. Investigation of similar effects in a sam-
ple including a group of individuals with a higher PRS for SCZ
(e.g. relatives of patients) may reveal more about the potential
SCZ-risk-related MDD subtype.
UK Biobank participants are also older than the general popu-
lation, with an average age of over 60 years, although a range of age
groups from middle to late adulthood are represented. Focusing on
this age group did, however, make it unlikely that subjects were yet
to be diagnosed with SCZ, meaning that our results do relate to the
effects of genetic risk only, rather than to SCZ itself. Another pos-
sible limitation was our measure of MDD, as it was derived from a
web-based questionnaire. However, the online CIDI-SF was the
most reliable method that could be efficiently used in such a
large sample, and provided clinically relevant information based
on DSM-IV diagnostic criteria. Finally, there were a number of
potential covariates that we were unable to include, as complete
data were unavailable at the time of analysis, for example, subjects’
use of alcohol, tobacco, other drugs and medications, age of dis-
order onset and disorder severity. This should be considered
when interpreting the current findings.
In summary, we tested for the presence of a distinct subtype of
MDD associated with high genetic risk for SCZ by exploring
interactive effects between these two variables on structural mea-
sures across the brain. Results were generally not significant, but
we did observe a significant interactive effect on cortical thickness
in rostral ACC for two PRS thresholds, which we were also able to
replicate in a second subsample. While the direction of this inter-
action was unexpected, our results indicate that differences
between MDD cases and controls in rostral ACC thickness are
significantly influenced by SCZ PRS. This finding, together with
related previous findings, suggest subtle differences in MDD
related to SCZ risk and rostral ACC, which could influence
important factors such as development of the disorder and
response to treatment.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S003329171900165X.
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